Benzimidazole: A Promising target for the development of novel drug molecules against breast cancer

Balgovind; Omprakash Goshain

doi:10.52711/0974-4150.2023.00050

Asian Journal of Research in Chemistry

ISSN

0974-4150 (Online)
0974-4169 (Print)

Submit Article

Benzimidazole: A Promising target for the development of novel drug molecules against breast cancer

Author(s): Balgovind, Omprakash Goshain

Email(s): omprakashgoshain@gmail.com

DOI: 10.52711/0974-4150.2023.00050

Address: Balgovind, Omprakash Goshain*
Department of Pharmaceutical Chemistry, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001, Uttar Pradesh, India.
*Corresponding Author

Published In: Volume - 16, Issue - 4, Year - 2023

View HTML

View PDF

ABSTRACT:
Breast cancer is considered as one of the deadliest diseases dominantly in developed and developing countries. Continuous research is required in order to design and develop better therapeutic agents for cancer treatment with more selectivity, efficacy and reduced toxicity. Fused heterocyclic ring system has been identified as a privileged structure by several researchers that can be used as a template for drug discovery and development in Medicinal Chemistry. Wide range of drugs with therapeutic potential contain hetero-aromatic bicyclic ring system as pharmacophore. According to various research outputs in the literature substituted benzimidazoles have wide range of pharmacological profiles with multi-targeting ability, making them an important basic nucleus for the design and development of novel therapeutic agents for the treatment of complex cancers including breast cancer, skin cancer, and blood cancer. In the presented article we have discussed research outputs by many scientists in the last few years that support the candidature of benzimidazole scaffold for the development of novel therapeutic agents against breast cancer along with their mechanism of action. This review also focuses on little introductory idea about benzimidazole nucleus and types of breast cancer.

Keywords:

Cite this article:
Balgovind, Omprakash Goshain. Benzimidazole: A Promising target for the development of novel drug molecules against breast cancer. Asian Journal of Research in Chemistry 2023; 16(4):303-0. doi: 10.52711/0974-4150.2023.00050

Cite(Electronic):
Balgovind, Omprakash Goshain. Benzimidazole: A Promising target for the development of novel drug molecules against breast cancer. Asian Journal of Research in Chemistry 2023; 16(4):303-0. doi: 10.52711/0974-4150.2023.00050 Available on: https://ajrconline.org/AbstractView.aspx?PID=2023-16-4-9

REFERENCES:
1.   World Health Organization. Available online: http://who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death (accessed on 21 July 2021).
2.   Choi HS et al. Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro. Molecules. 2021 Aug 24;26(17):5118. doi: 10.3390/molecules26175118. PMID: 34500557; PMCID: PMC8433818.
3.   Liang Y, Zhou Y, Deng S, Chen T. Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway. ChemMedChem. 2016 Oct 19;11(20):2339-2346. doi: 10.1002/cmdc.201600261. Epub 2016 Sep 28. PMID: 27677422.
4.   Baker JR et al. Modelling and Phenotypic Screening of NAP-6 and 10-Cl-BBQ, AhR Ligands Displaying Selective Breast Cancer Cytotoxicity in Vitro. ChemMedChem. 2021 May 6;16(9):1499-1512. doi: 10.1002/cmdc.202000721. Epub 2021 Feb 25. PMID: 33300308.
5.   Yadav S, Narasimhan B, Kaur H. Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era. Anticancer Agents Med Chem. 2016:16(11):1403-1425. doi: 10.2174/1871520616666151103113412. PMID: 26526461.
6.   Kashif Haider and Mohammad Shahar Yar. Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside. In Intechopen. Benzimidazole, Edited by Pravin K and Vinayak A. Intechopen, London. 2022; 1st ed: pp. 158. DOI: 10.5772/intechopen.101702
7.   Heba A. Ibrahim, Hanan M. Refaat. Versatile mechanisms of 2-substituted benzimidazoles in targeted cancer therapy. Future Journal of Pharmaceutical Sciences. 2020;6(41). DOIhttps://doi.org/10.1186/s43094-020-00048-8.
8.   Anichina K et al. 1H-benzimidazole-2-yl hydrazones as tubulin-targeting agents: Synthesis, structural characterization, anthelmintic activity and antiproliferative activity against MCF-7 breast carcinoma cells and molecular docking studies. Chem Biol Interact. 2021 Aug 25;345:109540. doi: 10.1016/j.cbi.2021.109540. Epub 2021 Jun 15. PMID: 34139148.
9.   Chojnacki K et al. Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1H-benzimidazol-1-yl)propan-1-ols-Intracellular TBBi-Based CK2 Inhibitors with Proapoptotic Properties. Int J Mol Sci. 2021 Jun 10;22(12):6261. doi: 10.3390/ijms22126261. PMID: 34200807; PMCID: PMC8230474.
10.   Karaaslan C, Bakar F, Goker H. Antiproliferative activity of synthesized some new benzimidazole carboxamidines against MCF-7 breast carcinoma cells. Z Naturforsch C J Biosci. 2018 Feb 23;73(3-4):137-145. doi: 10.1515/znc-2017-0067. PMID: 28902634.
11.   Al-Douh MH et al. Anti-proliferation effects of benzimidazole derivatives on HCT-116 colon cancer and MCF-7 breast cancer cell lines. Asian Pac J Cancer Prev. 2012;13(8):4075-9. doi: 10.7314/apjcp.2012.13.8.4075. PMID: 23098519.
12.   Błaszczak-Świątkiewicz K. Antiproliferative Aspect of Benzimidazole Derivatives' Activity and Their Impact on NF-κB Expression. Molecules. 2019 Oct 29;24(21):3902. doi: 10.3390/molecules24213902. PMID: 31671914; PMCID: PMC6864661.
13.   Chojnacki K et al. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases. Bioorg Chem. 2018 Oct; 80:266-275. doi: 10.1016/j.bioorg.2018.06.022. Epub 2018 Jun 22. PMID: 29966873.
14.   Zhang J et al. Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells. Bioorg Chem. 2017 Jun; 72:168-181. doi: 10.1016/j.bioorg.2017.04.005. Epub 2017 Apr 17. PMID: 28460359.
15.   Mostafa AS, Gomaa RM, Elmorsy MA. Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR-2 inhibitors with anti-breast cancer activity. Chem Biol Drug Des. 2019 Apr; 93(4):454-463. doi: 10.1111/cbdd.13433. Epub 2018 Nov 28. PMID: 30393973.
16.   Srour AM et al. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Bioorg Med Chem. 2020 Sep 15;28(18):115657. doi: 10.1016/j.bmc.2020.115657. Epub 2020 Jul 21. PMID: 32828424.
17.   Liang Y, Zhou Y, Deng S, Chen T. Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway. ChemMedChem. 2016 Oct 19;11(20):2339-2346. doi: 10.1002/cmdc.201600261. Epub 2016 Sep 28. PMID: 27677422.
18.   Galal SA et al. Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates. Eur J Med Chem. 2018 Feb 25;146:687-708. doi: 10.1016/j.ejmech.2018.01.072. Epub 2018 Feb 2. PMID: 29407991.
19.   Rasal NK, Sonawane RB, Jagtap SV. Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: Design, synthesis, in vitro anticancer and in silico ADME study. Bioorg Chem. 2020 Apr 97:103660. doi: 10.1016/j.bioorg.2020.103660. Epub 2020 Feb 11. PMID: 32086056.
20.   Dhanwal V et al. Self-assembled organic nanoparticles of benzimidazole analogue exhibit enhanced uptake in 3D tumor spheroids and oxidative stress induced cytotoxicity in breast cancer. Mater Sci Eng C Mater Biol Appl. 2019 Apr 97:467-478. doi: 10.1016/j.msec.2018.12.039. Epub 2018 Dec 19. PMID: 30678934.
21.   Nashaat S, Henen MA, El-Messery SM, Eisa H. Synthesis, state-of-the-art NMR-binding and molecular modeling study of new benzimidazole core derivatives as Pin1 inhibitors: Targeting breast cancer. Bioorg Med Chem. 2020 Jun 1;28(11):115495. doi: 10.1016/j.bmc.2020.115495. Epub 2020 Apr 11. PMID: 32307260.
22.   Thimmegowda NR et al. Synthesis, characterization and evaluation of benzimidazole derivative and its precursors as inhibitors of MDA-MB-231 human breast cancer cell proliferation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):432-5. doi: 10.1016/j.bmcl.2007.08.078. Epub 2007 Oct 24. PMID: 17981032.
23.   Shi DF et al. Antitumor benzothiazoles.. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem. 1996 Aug 16;39(17):3375-84. doi: 10.1021/jm9600959. PMID: 8765521.
24.   Azami Movahed M et al. Design, synthesis, and biological evaluation of new pyrazino[1,2-a]benzimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors. Arch Pharm (Weinheim). 2019 Feb 352(2):e1800265. doi: 10.1002/ardp.201800265. Epub 2018 Dec 18. PMID: 30561073.
25.   Zhen Y et al. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer. Theranostics. 2020 Jul 2;10(18):8080-8097. doi: 10.7150/thno.43473. PMID: 32724459; PMCID: PMC7381743.
26.   Zuo D et al. Methyl 5-[(1H-indol-3-yl)selanyl]-1H-benzoimidazol-2-ylcarbamate (M-24), a novel tubulin inhibitor, causes G2/M arrest and cell apoptosis by disrupting tubulin polymerization in human cervical and breast cancer cells. Toxicol In Vitro. 2017 Aug 42:139-149. doi: 10.1016/j.tiv.2017.04.019. Epub 2017 Apr 13. PMID: 28412508.
27.   Abdul Rahim AS et al. Microwave-assisted synthesis of sec/tert-butyl 2-arylbenzimidazoles and their unexpected antiproliferative activity towards ER negative breast cancer cells. J Enzyme Inhib Med Chem. 2013 Dec 28(6):1255-60. doi: 10.3109/14756366.2012.729828. Epub 2012 Oct 15. PMID: 23061895.
28.   Acar Çevik U et al. Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives as Aromatase Inhibitor. Molecules. 2020 Apr 2;25(7):1642. doi: 10.3390/molecules25071642. PMID: 32252458; PMCID: PMC7180718.
29.   Zhang L et al. Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer. Mol Biosyst. 2015 Nov 11(11):2860-6. doi: 10.1039/c5mb00466g. PMID: 26299935.
30.   Hsieh CY et al. Design and Synthesis of Benzimidazole-Chalcone Derivatives as Potential Anticancer Agents. Molecules. 2019 Sep 6;24(18):3259. doi: 10.3390/molecules24183259. PMID: 31500191; PMCID: PMC6767017.
31.   Reddy TS et al. Design, synthesis and biological evaluation of 1,3-diphenyl-1H-pyrazole derivatives containing benzimidazole skeleton as potential anticancer and apoptosis inducing agents. Eur J Med Chem. 2015 Aug 28;101:790-805. doi: 10.1016/j.ejmech.2015.07.031. Epub 2015 Jul 17. PMID: 26231080.
32.   Abdelgawad MA, Bakr RB, Omar HA. Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents. Bioorg Chem. 2017 Oct 74:82-90. doi: 10.1016/j.bioorg.2017.07.007. Epub 2017 Jul 15. PMID: 28772160.
33.   Singh R et al. Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation. Arch Pharm (Weinheim). 2021 Jul 354(7):e2000393. doi: 10.1002/ardp.202000393. Epub 2021 Mar 22. PMID: 33749032.
34.   Patil R et al. Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H⁺)-ATPase Inhibitors. Molecules. 2017 Sep 16;22(9):1559. doi: 10.3390/molecules22091559. PMID: 28926955; PMCID: PMC6151825.
35.   Sharma P et al. New (E)-1-alkyl-1H-benzo[d]imidazol-2-yl)methylene)indolin-2-ones: Synthesis, in vitro cytotoxicity evaluation and apoptosis inducing studies. European Journal of Medicinal Chemistry. 2016 Oct 21:122:584-600. doi:10.1016/j.ejmech.2016.07.019
36.   Kumar A et al. Solvent-free synthesis and anticancer activity evaluation of benzimidazole and perimidine derivatives. Mol Divers. 2018 Feb 22(1):113-127. doi: 10.1007/s11030-017-9790-3. Epub 2017 Nov 15. PMID: 29143160.
37.   Vashist N. et al. Synthesis and biological profile of substituted benzimidazoles. Chemistry Central Journal. 2018:12(125). https://doi.org/10.1186/s13065-018-0498-y
38.   Xu XL et al. Synthesis and cytotoxic activity of novel 1-((indol-3-yl)methyl)-1H-imidazolium salts. Bioorg Med Chem Lett. 2014 Nov 1;24(21):4926-30. doi: 10.1016/j.bmcl.2014.09.045. Epub 2014 Sep 23. PMID: 25301771.
39.   Paul K, Bindal S, Luxami V. Synthesis of new conjugated coumarin-benzimidazole hybrids and their anticancer activity. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3667-72. doi: 10.1016/j.bmcl.2012.12.071. Epub 2013 Jan 4. PMID: 23642480.
40.   Łukowska-Chojnacka E et al. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity. Bioorg Med Chem. 2016 Feb 15;24(4):735-41. doi: 10.1016/j.bmc.2015.12.041. Epub 2015 Dec 24. PMID: 26778657.
41.   Mochona B et al. Synthesis of Some Benzimidazole Derivatives Bearing 1,3,4-Oxadiazole Moiety as Anticancer Agents. Chem Sci Trans. 2015 Apr 4(2):534-540. doi: 10.7598/cst2015.1029. PMID: 26451350; PMCID: PMC4594831.
42.   Starcević K et al. Synthesis, antiviral and antitumor activity of 2-substituted-5-amidino-benzimidazoles. Bioorg Med Chem. 2007 Jul 1;15(13):4419-26. doi: 10.1016/j.bmc.2007.04.032. Epub 2007 Apr 25. PMID: 17482821.